Alpha 1-antitrypsin deficiency
- A1AT deficiency
- AAT deficiency
- Alpha 1 antitrypsin deficiency
- Alpha-1-antitrypsin deficiency
- GeneReviews provides current, expert-authored, peer-reviewed, full-text articles describing the application of genetic testing to the diagnosis, management, and genetic counseling of patients with specific inherited conditions. Click on the link to view the article on this topic.
- Orphanet Emergency Guidelines is an article which is expert-authored and peer-reviewed that is intended to guide health care professionals in emergency situations involving this condition.
The Childhood Liver Disease Research and Education Network (ChiLDREN) is a team of doctors, nurses, research coordinators, and research labs throughout the U.S., working together to improve the lives of people with rare liver diseases through research. Current studies are enrolling people with Alagille syndrome, alpha one-antitrypsin deficiency, bile acid synthesis defects, biliary atresia, cystic fibrosis liver disease, idiopathic neonatal hepatitis, mitochondrial hepatopathies, and progressive familial intrahepatic cholestasis. Click on the link above to learn more.
Visit the following link to find the participating research center nearest you.
- ClinicalTrials.gov lists trials that are studying or have studied Alpha 1-antitrypsin deficiency. Click on the link to go to ClinicalTrials.gov to read descriptions of these studies.
|Generic Name||Alpha1-Proteinase Inhibitor (Human)|
The FDA has approved this product to be used in this manner.
|For chronic replacement therapy of individuals having congenital deficiency of alpha1- proteinase inhibitor with clinically demonstrable panacinar emphysema.|
|More Information about this product||Drug Information Portal|